Results 161 to 170 of about 171,555 (309)

Inflammatory Hilar Mass and Cavernous Transformation in Disseminated Histoplasmosis: A Rare Cause of Noncirrhotic Portal Hypertension. [PDF]

ACG Case Rep J
Tippins K, Townsend EC, Wallace F, Phan H, Rohrer CT, Said A.   +5 more
europepmc   +1 more source

Portal Hypertension [PDF]

Postgraduate Medical Journal, 1947
openaire   +2 more sources

Portal hypertension [PDF]

Medical Journal Armed Forces India, 2012
openaire   +2 more sources

The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
Cirrhosis is frequently accompanied by varying degrees of lipid profile abnormalities. This study confirms that these profiles are differentially affected by disease etiology and progressively worsen—with significant reductions in TC, HDL‐C, and LDL‐C—as liver disease severity increases. TIPS improves lipid profiles, particularly by increasing HDL‐C in
Jiamin Xu, Qinnian Li, Lagan Kumar Manandhar, Bilian Zhu, Chenrui Zhang, Weimin Bao, Yingmei Tang   +6 more
wiley   +1 more source

Clinicopathological features of non-cirrhotic portal fibrosis in primary biliary cholangitis: a 15-year experience at a tertiary referral center. [PDF]

Front Med (Lausanne)
Wang X, Zhang L, Liu S, Zhang T, Wang T, Zhong D.   +5 more
europepmc   +1 more source

Chinese Registry on Transjugular Intrahepatic Portosystemic Shunts (CN‐TIPS): Protocol for a Registry‐Based, Prospective Prognostic Study

Portal Hypertension &Cirrhosis, EarlyView.
CN‐TIPS is a nationwide, multicenter prospective registry that will enroll 10,000 adults with portal hypertension undergoing transjugular intrahepatic portosystemic shunt in China, integrating perioperative clinical and hemodynamic metrics with standardized imaging (including computational modeling in a dedicated subcohort) and multi‐omics biospecimens,
Yi Xiang, Yong Lv, Hongwei Zhou, Jianbo Zhao, Meng Niu, Jiacheng Liu, Guangchuan Wang, Qi Zhang, Weizhong Zhou, Beijia Yu, Jun Chi, Guo Han, Jiawei Zhang, Long Gao, Wenjing Liu, Zhang Zhang, Tianyu Liu, Wuhua Guo, He Zhao, Gao‐Jun Teng, Xiaolong Qi   +20 more
wiley   +1 more source

Case Report: Preoperative treatment of portal hypertension by splenic artery embolization for safe major hepatectomy: experience in three patients. [PDF]

Front Surg
Gürel D, Güzelbey T, Aydın O, Kaya S, Bostancı Ö, Özden İ.   +5 more
europepmc   +1 more source

Microbubble‐Based Ultrasound Contrast Agents in Contrast‐Enhanced Ultrasonography for Managing Portal Hypertension in Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
As the hepatic venous pressure gradient (HVPG) remains the current gold standard for diagnosing portal hypertension in cirrhosis, its clinical application is limited by invasiveness, high cost, and restricted availability. Given the urgent need for noninvasive techniques to dynamically monitor portal vein pressure (PVP), contrast‐enhanced ...
Danping Huang, Zefeng Liu, Lingling Liu, Fen Huang, Wenjuan Wang, Guo Zhang   +5 more
wiley   +1 more source

Association of small intestinal bacterial overgrowth with portal hypertension in HCV-related cirrhosis: a cross-sectional study. [PDF]

Clin Exp Med
Salman T, El-Azab G, Khalil F, Elkazaz R, Helal A.   +4 more
europepmc   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source